Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK

European Journal of Pharmacology

Volumn 680, Issue 1-3, 2012, Pages 88-94

  Chen, Yen Ling ^a   Loh, Shih Hurng ^a   Chen, Jin Jer ^b,c,d   Tsai, Chien Sung ^a,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Akt; Cardiomyocyte apoptosis; Doxorubicin; Extracellular signal regulated kinase; Urotensin II

Indexed keywords

CASPASE 3; DNA; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UROTENSIN II;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART PROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; DRUG INTERACTIONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IN SITU NICK-END LABELING; MAP KINASE KINASE 1; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; UROTENSINS;

EID: 84862803866     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.01.034     Document Type: Article

References (36)

1. R.S. Ames, H.M. Sarau, J.K. Chambers, R.N. Willette, N.V. Aiyar, A.M. Romanic, C.S. Louden, J.J. Foley, C.F. Sauermelch, R.W. Coatney, Z. Ao, J. Disa, S.D. Holmes, J.M. Stadel, J.D. Martin, W.S. Liu, G.I. Glover, S. Wilson, D.E. McNulty, C.E. Ellis, N.A. Elshourbagy, U. Shabon, J.J. Trill, D.W. Hay, E.H. Ohlstein, D.J. Bergsma, and S.A. Douglas Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 Nature 401 1999 282 286
2. N. Bousette, F. Hu, E.H. Ohlstein, D. Dhanak, S.A. Douglas, and A. Giaid Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation J. Mol. Cell. Cardiol. 41 2006 285 295 (Pubitemid 44080219)
3. H.H. Chao, J.C. Liu, H.J. Hong, J.W. Lin, C.H. Chen, and T.H. Cheng l-Carnitine reduces doxorubicin-induced apoptosis through a prostacyclin- mediated pathway in neonatal rat cardiomyocytes Int. J. Cardiol. 146 2009 145 152
4. T.H. Cheng, N.L. Shih, S.Y. Chen, D.L. Wang, and J.J. Chen Reactive oxygen species modulate endothelin-I-induced c-fos gene expression in cardiomyocytes Cardiovasc. Res. 41 1999 654 662 (Pubitemid 29130629)
5. A.C. Childs, S.L. Phaneuf, A.J. Dirks, T. Phillips, and C. Leeuwenburgh Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio Cancer Res. 62 2002 4592 4598
6. A. Clerk, S.M. Cole, T.E. Cullingford, J.G. Harrison, M. Jormakka, and D.M. Valks Regulation of cardiac myocyte cell death Pharmacol. Ther. 97 2003 223 261 (Pubitemid 36167840)
7. A. Czarnecki Doxorubicin-induced cardiomyopathy Pol. Tyg. Lek. 38 1983 471 473
8. S.A. Douglas, L. Tayara, E.H. Ohlstein, N. Halawa, and A. Giaid Congestive heart failure and expression of myocardial urotensin II Lancet 359 2002 1990 1997 (Pubitemid 34663713)
9. G. Esposito, C. Perrino, A. Cannavo, G.G. Schiattarella, F. Borgia, A. Sannino, G. Pironti, G. Gargiulo, L.D. Serafino, A. Franzone, L. Scudiero, P. Grieco, C. Indolfi, and M. Chiariello EGFR trans-activation by urotensin II receptor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy Basic Res. Cardiol. 106 2011 577 589
10. A.P. Fontes-Sousa, C. Bras-Silva, A.L. Pires, D. Monteiro-Sousa, and A.F. Leite-Moreira Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling Naunyn Schmiedebergs Arch. Pharmacol. 376 2007 107 115
11. M.A. Frias, U. Lang, C. Gerber-Wicht, and R.W. James Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis Cardiovasc. Res. 85 2010 118 126
12. P. Fu, and M.O. Arcasoy Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis Biochem. Biophys. Res. Commun. 354 2007 372 378 (Pubitemid 46161367)
13. R. Fukazawa, T.A. Miller, Y. Kuramochi, S. Frantz, Y.D. Kim, M.A. Marchionni, R.A. Kelly, and D.B. Sawyer Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt J. Mol. Cell. Cardiol. 35 2003 1473 1479 (Pubitemid 37491190)
14. J. Ghosh, J. Das, P. Manna, and P.C. Sil The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis Biomaterials 32 2011 4857 4866
15. D. Gruson, M.F. Rousseau, S.A. Ahn, F. van Linden, and J.M. Ketelslegers Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers Peptides 27 2006 1527 1531
16. D. Gruson, A. Ginion, N. Decroly, P. Lause, J.L. Vanoverschelde, J.M. Ketelslegers, L. Bertrand, and J.P. Thissen Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway Peptides 31 2010 1326 1333
17. D.J. Hausenloy, and D.M. Yellon Survival kinases in ischemic preconditioning and postconditioning Cardiovasc. Res. 70 2006 240 253
18. D.J. Hausenloy, M.M. Mocanu, and D.M. Yellon Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning Cardiovasc. Res. 63 2004 305 312 (Pubitemid 38900844)
19. D.G. Johns, Z. Ao, D. Naselsky, C.L. Herold, K. Maniscalco, L. Sarov-Blat, K. Steplewski, N. Aiyar, and S.A. Douglas Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators Naunyn Schmiedebergs Arch. Pharmacol. 370 2004 238 250 (Pubitemid 40063823)
20. S.Q. Khan, S.S. Bhandari, P. Quinn, J.E. Davies, and L.L. Ng Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans Int. J. Cardiol. 117 2007 323 328 (Pubitemid 46507623)
21. M. Klaiber, M. Kruse, K. Volker, J. Schroter, R. Feil, M. Freichel, A. Gerling, S. Feil, A. Dietrich, J.E. Londono, H.A. Baba, J. Abramowitz, L. Birnbaumer, J.M. Penninger, O. Pongs, and M. Kuhn Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2 Basic Res. Cardiol. 105 2010 583 595
22. A.R. Kompa, B.H. Wang, A. Phrommintikul, P.Y. Ho, D.J. Kelly, D.J. Behm, S.A. Douglas, and H. Krum Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy Peptides 31 2010 1523 1530
23. E.A. Lefrak, J. Pitha, S. Rosenheim, and J.A. Gottlieb A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 32 1973 302 314
24. Li Amlodipine inhibits TNF-alpha production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway Int. Immunopharmacol. 9 2009 1032 1041
25. M. Lim, S. Honisett, C.D. Sparkes, P. Komesaroff, A. Kompa, and H. Krum Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure Circulation 109 2004 1212 1214 (Pubitemid 38372777)
26. D.J. Lips, O.F. Bueno, B.J. Wilkins, N.H. Purcell, R.A. Kaiser, J.N. Lorenz, L. Voisin, M.K. Saba-El-Leil, S. Meloche, J. Pouyssegur, G. Pages, L.J. De Windt, P.A. Doevendans, and J.D. Molkentin MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo Circulation 109 2004 1938 1941 (Pubitemid 38544482)
27. J.C. Liu, C.H. Chen, J.J. Chen, and T.H. Cheng Urotensin II induces rat cardiomyocyte hypertrophy via the transient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor Mol. Pharmacol. 76 2009 1186 1195
28. Milano Phosphorylation of phosphatidylinositol-3-kinase-protein kinase B and extracellular signal-regulated kinases 1/2 mediate reoxygenation-induced cardioprotection during hypoxia Exp. Biol. Med. (Maywood) 235 2010 401 410
29. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229 (Pubitemid 38720829)
30. D. Onan, L. Pipolo, E. Yang, R.D. Hannan, and W.G. Thomas Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases Mol. Endocrinol. 18 2004 2344 2354 (Pubitemid 39215262)
31. H.C. Prosser, M.E. Forster, A.M. Richards, and C.J. Pemberton Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury Peptides 29 2008 770 777 (Pubitemid 351522361)
32. F.D. Russell, D. Meyers, A.J. Galbraith, N. Bett, I. Toth, P. Kearns, and P. Molenaar Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure Am. J. Physiol. Heart Circ. Physiol. 285 2003 H1576 H1581
33. P.A. Salem Advances in cancer chemotherapy J. Med. Liban. 28 1975 9 24
34. B. Vanhaesebroeck, S.J. Leevers, G. Panayotou, and M.D. Waterfield Phosphoinositide 3-kinases: a conserved family of signal transducers Trends Biochem. Sci. 22 1997 267 272 (Pubitemid 27310948)
35. H. Vaudry, J.C. Do Rego, J.C. Le Mevel, D. Chatenet, H. Tostivint, A. Fournier, M.C. Tonon, G. Pelletier, J.M. Conlon, and J. Leprince Urotensin II, from fish to human Ann. N. Y. Acad. Sci. 1200 2010 53 66
36. C. Widmann, S. Gibson, M.B. Jarpe, and G.L. Johnson Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human Physiol. Rev. 79 1999 143 180 (Pubitemid 29056951)